Home > Institute Collections > W500 > Tumor Necrosis Factor α: Taking a Personalized Road in Cancer Therapy. > print

001     306231
005     20251118111026.0
024 7 _ |a 10.3389/fimmu.2022.903679
|2 doi
024 7 _ |a pmid:35663982
|2 pmid
024 7 _ |a pmc:PMC9157545
|2 pmc
037 _ _ |a DKFZ-2025-02460
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Ben-Baruch, Adit
|b 0
245 _ _ |a Tumor Necrosis Factor α: Taking a Personalized Road in Cancer Therapy.
260 _ _ |a Lausanne
|c 2022
|b Frontiers Media
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1763460569_1939189
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #DKFZ-MOST-Ca187#
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a TNFR1
|2 Other
650 _ 7 |a TNFR2
|2 Other
650 _ 7 |a cancer
|2 Other
650 _ 7 |a personalized therapy
|2 Other
650 _ 7 |a tumor necrosis factor α/TNFα
|2 Other
650 _ 7 |a Receptors, Tumor Necrosis Factor, Type I
|2 NLM Chemicals
650 _ 7 |a Receptors, Tumor Necrosis Factor, Type II
|2 NLM Chemicals
650 _ 7 |a Tumor Necrosis Factor-alpha
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Neoplasms: drug therapy
|2 MeSH
650 _ 2 |a Receptors, Tumor Necrosis Factor, Type I
|2 MeSH
650 _ 2 |a Receptors, Tumor Necrosis Factor, Type II
|2 MeSH
650 _ 2 |a Tumor Necrosis Factor-alpha
|2 MeSH
773 _ _ |a 10.3389/fimmu.2022.903679
|g Vol. 13, p. 903679
|0 PERI:(DE-600)2606827-8
|p 903679
|t Frontiers in immunology
|v 13
|y 2022
|x 1664-3224
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT IMMUNOL : 2022
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-12-29T15:23:07Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-12-29T15:23:07Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-12-29T15:23:07Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2023-12-29T15:23:07Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-28
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-28
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b FRONT IMMUNOL : 2022
|d 2024-12-28
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-28
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-28
980 _ _ |a journal
980 _ _ |a I:(DE-He78)W500-20160331
980 _ _ |a I:(DE-He78)W510-20160331
980 1 _ |a EXTERN4COORD

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21